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Abstract
Introduction
Coronary heart disease (CHD) remains a leading cause of death in
the United States. The Framingham Risk Score (FRS) was de-
veloped to help clinicians in determining their patients’ CHD risk.
We hypothesize that the FRS will be significantly predictive of
CHD events  among men in  the  Aerobics  Center  Longitudinal
Study (ACLS) population.
Methods
Our study consisted of 34,557 men who attended the Cooper Clin-
ic in Dallas, Texas, for a baseline clinical examination from 1972
through 2002. CHD events included self-reported myocardial in-
farction or revascularization or death due to CHD. During the 12-
year follow-up 587 CHD events occurred. Multivariable-adjusted
hazard ratios generated from ACLS analysis were compared with
the application of FRS to the Framingham Heart Study (FHS).
Results
The ACLS cohort produced similar hazard ratios to the FHS. The
adjusted Cox proportional hazard model revealed that men with
total cholesterol of 280 mg/dL or greater were 2.21 (95% confid-
ence interval (CI), 1.59–3.09) times more likely to have a CHD
event than men with total cholesterol from 160 through 199mg/dL;
men with diabetes were 1.63 (95% CI,  1.35–1.98) times more
likely to experience a CHD event than men without diabetes.
Conclusion
The FRS significantly predicts CHD events in the ACLS cohort.
To the best of our knowledge, this is the first report of a large,
single-center cohort study to validate the FRS by using extensive
laboratory and clinical measurements.
Introduction
Coronary heart disease (CHD) remains one of the leading causes
of death in the United States, accounting for approximately 17%
of overall national health care expenditures (1). CHD is the accru-
al of plaque in the arteries of the heart (2) that supply the blood for
maintaining normal cardiac function. The accumulation of plaque
narrows the heart’s arteries and reduces blood flow to the heart
muscle. The lack of oxygen-rich blood to portions of the heart
muscle leads to ischemia of myocardial tissues and consequent al-
teration of heart function. CHD also can be caused by the depos-
ition of fat beneath the endothelium, reducing the elasticity of ar-
teries (2). This arterial damage is caused by an array of significant
risk factors such as hypertension (3), hypercholesterolemia (4),
diabetes (5),  and smoking (6).  However,  these risk factors are
modifiable  through  individual  and  population-level  behavior
change; through close monitoring of cholesterol, blood glucose,
and other risk factors; and by treating any of these risk factors that
are above acceptable ranges with medication such as statins or in-
sulin. As a result, many countries have experienced a decrease of
CHD incidence in the past 30 years (7).
Several risk scores have been developed to provide guidance to
clinicians on their patients’ risk for CHD (8,9). The Framingham
Risk Score (FRS) (9,10) is the CHD risk score most widely used
by clinicians across the globe (11). The FRS originated from the
Framingham Heart Study (FHS), a relatively homogeneous cohort
residing in Framingham, Massachusetts (9), and has been applied
and  validated  in  a  variety  of  different  populations  (12,13).
However, the study of Kagan et al (13) lacked complete congru-
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ency with FRS methodology, and other studies such as those of
Lee et  al  (12) and Fried et  al  (14) had relatively small  sample
sizes. A recent publication updated the 1998 FRS and developed a
new risk score that predicted an individual’s cardiovascular dis-
ease risk instead of the CHD outcome (15). For this study, we
chose to investigate CHD outcomes as they comprise the majority
of cardiovascular disease events (16).
Our research aims to expand on recent validation studies (17) that
used the Aerobics Center Longitudinal Study (ACLS) cohort and
the measured outcome of 10-year risk for CHD. ACLS provides a
larger cohort to validate FRS than FHS or other previous studies,
and FRS has yet to be applied to this cohort. Extensive measures
of FRS components and CHD outcomes are available on the more
than 40,000 participants (18) in the ACLS cohort. Our objective
was to test the hypothesis that the FRS will be significantly pre-
dictive of CHD events among men in the ACLS population.
Methods
Study population
ACLS is an observational longitudinal study whose members were
patients of the Cooper Clinic, Dallas, Texas, where they received a
preventive medical examination and counseling on health behavi-
ors during periodic visits. The Cooper Clinic serves anyone who
elects to come for an examination, and patients come from all 50
states. During the patients’ medical examination, they were in-
formed of the ACLS, asked to participate, and if they agreed to
participate, they consented to follow-up surveillance. The ACLS
protocol was annually reviewed and approved by the Cooper Insti-
tute’s institutional review board.
Participants were examined at least once from 1972 through 2002
at the Cooper Clinic. The cohort consisted mostly of patients in
the middle and high socioeconomic groups: approximately 80%
had college degrees (19). The mean baseline age of the cohort was
42 years (20) and consisted mostly of men (75%) and non-Hispan-
ic whites (>95%).
Although ACLS is not a representative sample of the entire US
population, a comparison of median values of specific physiolo-
gical variables show similarity to representative population data
(21).
A large number of women were enrolled in ACLS (n = 11,276);
however, women were excluded from this analysis because of the
small number of CHD events (n = 45) during the follow-up period.
The following inclusion criteria were applied to the ACLS cohort
participants for the current study: 1) age at baseline examination
from 30 to 74 years, 2) complete data for outcome and predictor
variables, and 3) free of CHD diagnosis or cancer diagnosis at
baseline. To control for any unmeasured confounders that may
have caused early drop-out, men with less than 1 year of follow-up
were excluded from the study’s cohort (Figure 1).
Figure 1. Study flow and Aerobic Center Longitudinal Study inclusion criteria
depicting final sample size and coronary heart disease event frequency. Men
with complete Framingham Risk Score data and body mass index ≥ 18.5
kg/m2 were included in the analysis. Abbreviations: FRS, Framingham Heart
Study; CHD, coronary heart disease; BMI, body mass index.
 
Clinical examination
Trained technicians followed standardized protocols in conduct-
ing  each  measurement.  The  baseline  clinical  examination  in-
cluded a  personal  and family  medical  history,  anthropometric
measurements, a 12-hour fasting blood chemistry including gluc-
ose and cholesterol measurements, electrocardiogram, blood pres-
sure assessment, and a maximal exercise test (21,22).
CHD was the primary end point  being investigated.  CHD was
defined as the self-report of myocardial infarction or revasculariz-
ation (including, bypass, coronary balloon, angioplasty, or stent)
or death due to CHD. Participants reported their history of infarc-
tion or revascularization and incident date through a mail-back
questionnaire administered in 1982, 1986, 1990, 1995, 1999, and
2004. Deaths among study participants were identified from the
National Center for Health Statistic’s National Death Index. Inter-
national Classification of Disease (ICD), Ninth Revision, codes
410.0–414.0 and Tenth Revision, codes I20–I25, were used to
identify CHD as the primary cause of death. According to the FRS
follow-up time definition, the maximal follow-up time was 12
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years. The 12-year follow-up was used in the regression and sur-
vival analysis and then adapted to provide 10-year CHD incid-
ence estimates.
The covariates considered for analyses in the ACLS population
mimicked the variables included in the recently updated FRS (10).
Hypertension was divided into 4 categories according to systolic
blood pressure and diastolic blood pressure. Systolic blood pres-
sure was categorized into 4 levels: <130 mm Hg, 130–139 mm
Hg, 140–159 mm Hg, or ≥160 mm Hg, and diastolic blood pres-
sure was categorized into 4 levels: <85 mm Hg, 85–89 mm Hg,
90–99 mm Hg, and ≥ 100 mm Hg. When an participant’s blood
pressure fell  into different categories for systolic and diastolic
blood pressure, the higher category was chosen for categorization.
For example, if a participant’s blood pressure was 130/80 (systol-
ic blood pressure/diasystolic blood pressusre), the corresponding
categories for systolic blood pressure would be 2, and the diastol-
ic blood pressure category would be 1. To determine the hyperten-
sion category, the higher classification would be chosen and the
hypertension categorization would be 2 in this example. Hyperten-
sion definition was made without regard to a participant’s use of
antihypertensive medications. The definition of hypertension par-
allels the FRS definition (10).
Total  cholesterol  was  grouped  into  four  levels:  <200  mg/dL,
200–239 mg/dL, 240–279 mg/dL, and ≥ 280 mg/dL. High-density
lipoprotein was categorized as: <35 mg/dL, 35–59 mg/dL, and ≥
60 mg/dL. A 12-hour fasting glucose >140 mg/dL classified an in-
dividual as having diabetes. Smoking status was dichotomized as
current smoker or nonsmoker. All categorizations and definitions
were analogous to FRS covariate groupings (10).
Statistical analysis
Descriptive statistics were generated to compare the ACLS popu-
lation with the FRS population. Men in each cohort were com-
pared on mean age; percentage within each category in hyperten-
sion, total cholesterol, and HDL; percentage with diabetes, and
percentage of current smokers. Univariate Cox Proportional Haz-
ard models were performed for the CHD events and each covari-
ate to determine each characteristic’s predictive power. Cox Sur-
vival analyses were conducted to determine the 10-year CHD risk
for the ACLS male population. The fully adjusted Cox Proportion-
al Hazard model included age, blood pressure, total cholesterol,
high  density  lipoprotein  cholesterol,  diabetes  diagnosis,  and
smoking status.
Predictive accuracy was determined through the concordance stat-
istic (C statistic) associated with the receiver operating character-
istic (ROC) curve. The ROC curve measures the discrimination
power of these diagnostic markers for the CHD outcome. The
Hosmer-Lemeshow statistic is used to assess calibration and is a
χ2 test calculated by sorting the sample by estimated probability of
success (23). The higher the C statistic, the better the prediction. A
limitation of the Hosmer-Lemeshow test is that it is not recom-
mended for sample sizes larger than 25,000. A sensitivity analysis
was performed following the recommendations of Paul et al (23),
and the ACLS sample (n = 34,557) and a smaller 10,000 sample
cohort were randomly selected. To satisfy this limitation, the Hos-
mer-Lemeshow test was performed on a randomly selected cohort
(n = 10,000), and  P value of P > .05 represents no significant dif-
ference between predicted and observed events. All analyses were
performed using SAS version 9.3.
Results
During the 12-year follow-up period (284,572 person-years of ex-
posure), 587 men had a CHD event. The incidence rate was 20 per
10,000 person-years. The ACLS cohort had approximately 32,000
more participants (Table 1) than the FHS, and participants were,
on average, younger (P < .001). FHS had a higher proportion of
people with diabetes (5.0%) and smokers (40.0%) than the ACLS
cohort, which had 1.5% and 17.0%, respectively (P < .001) (Table
1).
When the ACLS cohort is stratified by CHD status, men who ex-
perienced a CHD event during the 12-year follow-up were signi-
ficantly  different  on all  predictor  variables;  that  is,  they were
older, had higher blood pressure, and were in the top 2 categories
for high-density lipoprotein cholesterol. Among those men who
experienced CHD during follow-up, 4.6% had diabetes and 23.3%
were smokers compared with 1.47% (P < .001) with diabetes and
16.8% current smokers  (P < .001) who did not experience CHD
(Table 2).
The covariates based on the FRS were all significant when ap-
plied to the men in ACLS (Table 3). The hazard ratios (HRs) re-
ported from FHS by D’Agostino et al (2001) (17) were similar to
the ACLS fully adjusted HRs. The fully adjusted HRs show that
men with Stage I hypertension (HR = 1.41; 95% confidence inter-
val [CI], 1.16–1.72) have significantly higher risk of CHD than
men with optimal or normal blood pressure. Men with total cho-
lesterol at or greater than 280mg/dL were more than twice (HR,
2.21; 95% CI, 1.59–3.09) as likely to have a CHD event than men
with total cholesterol between 160 and 199mg/dL.  Men with dia-
betes were 1.82 (95% CI, 1.23–2.70) times more likely to experi-
ence a CHD event than men without diabetes. Current smokers
also had a significantly higher risk (HR, 1.63; 95% CI, 1.35–1.98)
for CHD than nonsmokers during the 12-year follow-up.
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The C statistic (area under the curve) obtained from the receiver
operating  characteristic  (ROC)  curve  was  0.7697  (95%  CI,
0.7523–0.7871) (Figure 2). The Hosmer-Lemeshow test reported
no significant lack of fit for the model ( P = .88), and we failed to
reject the null hypothesis that states there is no significant differ-
ence between the predicted and observed values of the outcome
variable.
Figure 2. Receiver operating characteristic curve representing the predictive
ability  of  the  Framingham  Risk  Score  applied  to  the  Aerobics  Center
Longitudinal Study cohort after a 12-year follow-up. The Hosmer-Lemeshow C
statistic  is  represented  by  the  Area  Under  the  Curve  (C  =  0.7697,  95%
confidence interval, 0.7523–0.7871).
 
Discussion
The FRS significantly predicts CHD events occurring during the
12-year follow-up in the ACLS, which was a much larger study
than the original FHS. In addition to our main finding, we also
found that age, blood pressure, total cholesterol, high-density lipo-
protein cholesterol, diabetes diagnosis, and smoking status were
associated with CHD events. The relative risks were congruent
with the those reported from the FHS (17) and previous studies
(12,13).
Elevated blood pressure creates more strain for the heart, which
can cause stiffness of the heart muscle (2) or create microscopic
tears in the walls that may develop into scar tissue (2). Myocardi-
al ischemia is common among patients with hypertension (3,5),
and  reports  from  the  FHS  showed  that  hypertension  was  the
primary cause of congestive heart failure in 35% of cases (24).
Men with diabetes are also at increased risk for CHD (25), and ad-
ditional research shows that people with both diabetes and hyper-
tension have a higher incidence of heart disease than people with
diabetes or hypertension alone (5).
Doyle et al published the findings of a study that examined the as-
sociation between smoking and CHD (26) in two prospective stud-
ies: The FHS and the cohort from the Albany, New York, civil
service study, with a combined study population of over 1,800
men without CHD (26). The Doyle et al study concluded that men
with elevated systolic blood pressure and elevated total cholester-
ol who smoked were at a 1.8 (P < .05) times higher risk of prema-
ture mortality than men with elevated systolic blood pressure and
elevated total cholesterol who did not smoke (26). Our findings
are also in line with the Physicians’ Health Study, which reported
significant effects of HDL cholesterol and total cholesterol on
CHD (17).
Other researchers investigated FRS’s predictability in various pop-
ulations. The Honolulu Heart Study began in 1965 with the over-
all goal of standardizing cardiovascular examinations (13). The
cohort comprised Japanese American men born between 1900 and
1919 whose data were updated with information from their World
War II Selective Service files; the final population comprised ap-
proximately 8,000 men free of CHD on baseline examination at
study initiation (13). Cigarette smoking, cholesterol levels, blood
pressure, sum of arm and back skinfold measurements , and uric
acid levels were significant predictors of CHD; however, glucose
intolerance showed no significant relationship to CHD. The lack
of congruency in the significant  results  between the Honolulu
Heart Study, FHS, and ACLS may be due to the Honolulu Heart
Study population being at low risk of CHD (ie, CHD incidence
observed in the Honolulu Study was about half that of the FHS).
To the best of our knowledge, this is the first large, single-center,
prospective cohort to validate the FRS with the same level of pre-
cision as that of the FHS. The present study expands on previous
research through the improvement of internal validity by using ob-
jectively measured clinical data.
A limitation of the ACLS cohort (similar to an FHS limitation) is
the  homogeneity  of  the  study  population’s  sociodemographic
factors. This limitation was explored through comparison analysis
between ACLS and 2 large population-based cohorts; ACLS res-
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ults were found to be similar to the results of the Lipid Research
Clinics Prevalence Survey and the Canada Fitness Survey (27). It
should be noted that ACLS homogeneity may be a strength be-
cause it  improves internal  validity by controlling for potential
demographic  confounders  such  as  education,  socioeconomic
status, and race/ethnicity; however, generalizations must be made
cautiously, and future research should be conducted on more di-
verse populations. Unlike the FHS finding, the ACLS found that
having stage II–IV hypertension was not significantly associated
with CHD, which may be due to the small proportion (4.93%) of
the ACLS’s cohort who were in this group.
Although CHD remains one of the leading causes of death in the
United States, the prevalence of CHD has decreased since 2004
(28), a reduction that can be largely attributed to better medical
treatment and improvement in CHD risk profiles. The FRS was
developed to assist clinicians in estimating their patients’ absolute
risk for CHD (17). This study further evaluates FRS performance
in the larger ACLS cohort and strictly followed the FHS methodo-
logy, which does not control for other CHD risk factors such self-
rated health status (29), family history of CHD (30), and cardi-
orespiratory fitness (18). Future research should focus on expand-
ing the FRS to include other modifiable risk factors. Community
interventions and education programs should continue to target
these CHD risk factors to further the prevention of heart disease.
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Tables
Table 1. Comparison Between Demographic Characteristics of Men Free of Coronary Vascular Disease at Baseline in the Framing-
ham Heart Study (FHS) and the Aerobics Center Longitudinal Study (ACLS)a
Risk Factor Study Comparisonb
FHSc (n = 2,439) ACLS (n = 34,557)
Age range, y 30–74 30–74
Mean age, y 48.30 44.82
Blood pressure, (mm Hg)
Optimal and normal (SBP <130, DBP <85) 44.00 59.85
High normal (SBP  130–139, DBP 85–89) 20.00 16.24
Stage I hypertension (SBP 140–159, DBP 90–99) 23.00 18.98
Stage II–IV hypertension (SBP ≥160, DBP ≥100) 13.00 4.93
Total cholesterol (mg/dL)
<160 7.00 9.34
160-199 31.00 34.36
200-239 39.00 36.67
240-279 17.00 15.10
≥280 6.00 4.53
High-density lipoprotein cholesterol (mg/dL)
<35 19.00 16.24
35-59 70.00 70.97
≥60 11.00 12.79
Diabetes 5.00 1.52
Current smoker 40.00 16.95
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure.
a Numbers are expressed as percentages unless otherwise stated.
b Independent t test was used to determine statistically significant difference in age between FHS and ACLS participants; proportion test calculated the statistical
difference for each level of blood pressure, total cholesterol, high-density lipoprotein cholesterol, diabetes, and current smoking between FHS and ACLS parti-
cipants. All proportion tests were significant with a P value < .001.
c FHS, Framingham Risk Score descriptive statistics referenced from D'Agostina et al (17).
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Table 2. Comparison Between Demographic Characteristics of Men With and Without a Coronary Heart Disease (CHD) Event in the
Aerobic Center Longitudinal Study (ACLS)a
RISK FACTOR CHD Event Comparison within ACLSb
No CHD (n = 33,970) With CHD (n = 587)
Median follow-up time (IQR)
10.94
(3.82, 12.00)
5.66
(2.94, 8.93)
Age, range (years) 30-74 30-73
Mean age, y 44.70 51.91
Blood pressure, (mm Hg)
Optimal and normal (SBP <130, DBP <85) 60.06 47.53
High normal (SBP 130–139, DBP 85–89) 16.18 19.76
Stage I hypertension (SBP 140–159, DBP
90–99) 18.85 26.41
Stage II-IV hypertension (SBP ≥160, DBP ≥100) 4.90 6.30
Total cholesterol (mg/dL)
<160 9.44 3.92
160–199 34.62 19.59
200–239 36.60 40.37
240–279 14.88 27.60
≥280 4.46 8.52
High-density lipoprotein cholesterol (mg/dL)
<35 16.08 25.55
35–59 71.05 66.44
≥60 12.88 8.01
Diabetes 1.47 4.60
Current smoker 16.84 23.34
Abbreviations: IQR = interquartile range; SBP, systolic blood pressure; DBP, diastolic blood pressure.
a The numbers are percentages unless otherwise stated.
b χ2 test was performed to calculate statistical difference between the group with and without CHD. All comparisons were significant at P < 0.05.
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Table 3. Comparison Between Hazard Ratios for Coronary Heart Disease (CHD) Events for the Framingham Heart Study (FHS) Co-
hort and the Aerobics Center Longitudinal Study (ACLS) Cohort
Risk Factor FHSa ACLS 12y Follow-up
Unadjusted Fully Adjustedb
HR 95% CI HR 95% CI HR 95% CI
Age, y 1.05 1.04–1.06 1.09 1.08–1.10 1.09 1.08–1.10
Blood pressure, mm Hg
Optimal and normal (SBP <130,
DBP <85) 1.00 [Reference] 1.00 [Reference] 1.00 [Reference]
High normal  (SBP 130–139,
DBP 85–89 1.31 0.98–1.76 1.66 1.33–2.06 1.33 1.07–1.66
Stage I hypertension (SBP
140–159, DBP 90–99) 1.67 1.28–2.18 1.95 1.60–2.38 1.41 1.16–1.72
Stage II-IV hypertension  (SBP
≥160, DBP ≥100) 1.84 1.37–2.06 1.94 1.37–2.73 1.23 0.87–1.74
Total cholesterol (mg/dL)
<160 0.69 0.31–1.52 0.77 0.49–1.21 0.82 0.52–1.28
160–199 1.00 [Reference] 1.00 [Reference] 1.00 [Reference]
200–239 1.77 1.25–2.50 1.85 1.48–2.31 1.59 1.27–1.99
240–279 2.10 1.43–3.10 2.90 2.28–3.68 2.37 1.86–3.01
≥280 2.29 1.39–3.76 2.74 1.97–3.83 2.21 1.59–3.09
High density lipoprotein cholesterol (mg/dL)
<35 1.47 1.16–1.86 1.59 1.32–1.92 1.60 1.32–1.94
35–59 1.00 [Reference] 1.00 [Reference] 1.00[Reference]
≥60 0.56 0.37–0.83 0.66 0.49–0.90 0.60 0.44–0.81
Diabetes 1.50 1.06–2.13 3.45 2.34–5.07 1.82 1.23–2.70
Smoking status 1.68 1.37–2.06 1.60 1.32–1.93 1.63 1.35–1.98
Abbreviations: HR, hazard ratio; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure.
a Framingham Heart Study hazard ratios are from Wilson et al (10).
b Fully adjusted model included age, blood pressure, total cholesterol, high density lipoprotein levels, diabetes diagnosis, and smoking status.
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